Ferran Ballesca

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 03, 2023

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.

Journal: International journal of dermatology

Published: December 28, 2022

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Journal: Dermatologic therapy

Published: August 23, 2022

Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.

Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.

Journal: Dermatologic therapy

Published: May 17, 2022

High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.

High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.

Journal: International journal of dermatology

Published: September 14, 2021

The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.

The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.

Journal: The Journal of dermatological treatment

Published: April 29, 2021

Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience.

Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience.

Journal: Actas dermo-sifiliograficas

Published: April 06, 2021

Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain.

Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain.

Journal: Dermatology and therapy

Published: September 28, 2020

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Journal: Journal of the American Academy of Dermatology

Published: August 04, 2020

Large Carcinoma of the Scalp Invading the Meninges.

Large Carcinoma of the Scalp Invading the Meninges.

Journal: Actas dermo-sifiliograficas

Published: February 09, 2019

Paradoxical eczematous reaction to ixekizumab.

Paradoxical eczematous reaction to ixekizumab.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 29, 2018

Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.

Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.

Journal: The Journal of dermatological treatment

Published: April 24, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026